Are we getting an opportunity now to buy ResMed?

Michael Gable

The share price of ResMed (RMD) has shed almost 10 per cent since the start of August. It’s now trading on a P/E of ~20x, compared to ~24x around the time of their fiscal year result. There are however some concerns in the market about an expected impact on gross margins from pricing pressure from its US customers. Looking at the chart, we are can also identify some key levels that RMD needs to respect. (VIEW LINK)


Comments

Please sign in to comment on this wire.